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Introduction. This is the case of a young male patient who presented to his family physician with atypical left foot pain, which
was extremely resistant to analgesia and caused signiﬁcant disability. Despite extensive investigations, the cause of his pain was
not identiﬁed until 18 months after his initial symptoms, when the oﬃcial diagnosis of malignant peripheral nerve sheath tumour
(MPNST) was made. Detailed review of the patient’s past history established the diagnosis of type I neuroﬁbromatosis (NF-
1), previously undetected. Discussion. NF-1 is an autosomal dominant genetic disorder caused by loss of function mutations of
the NF1 gene in chromosome 17. Patients with this condition are at increased risk for developing MPNSTs which, however, are
treatableonlyinearlystages.Conclusion.AlthoughmonitoringNF-1patientsforthedevelopmentofMPNSTsiscommonpractice,
the index of clinical suspicion in patients without an established NF-1 diagnosis is low. Any atypical pain in young adults should
raise the possibility of this malignancy, and this case illustrates the fact that MPNSTs can be the ﬁrst manifestation of NF-1 in
patients previously undiagnosed with the disease.
1.CaseReport
A 24-year-old male smoker presented to his GP with a 6-
month history of right foot pain extending from the base of
the ﬁrst toe to the plantar surface of the foot. The pain was
ﬂuctuating in severity, did not correlate with speciﬁc activ-
ities,andwasonlypartiallyrelievedwithcommonanalgesics.
The patient’s work involved prolonged standing and heavy
lifting. He had had bilateral pes planus and valgus heels dur-
ing his childhood but had been asymptomatic for several
years. Two abdominal nodules had been excised by a derma-
tologist two years prior to the onset of his presenting com-
plaint. The histopathology report conﬁrmed they were a ﬁ-
broma and a leiomyoma of no particular clinical signiﬁ-
cance. Apart from a few other minor injuries, his past medi-
cal and surgical history was otherwise unremarkable.
The pain was attributed to the patient’s previous pes pla-
nus deformity and was treated conservatively with common
analgesia by the GP. Over the next three months the pain did
not resolve and the patient was referred to the local ortho-
pedics outpatient clinic. Extensive X-ray studies and blood
tests including inﬂammatory and immunological markers
were all normal, and the patient was referred to Orthotics
for foot arch support.
Despite the arch support, the pain progressively wors-
ened over the next 6 months. A foot MRI revealed mild, early
degenerative 1st MTP joint changes with a small amount of
fusion, but no other abnormalities. The diagnosis of reﬂex
sympatheticdystrophywasalsoconsideredandsupportedby
the ﬁndings of a radionuclide isotope scan. Although rocker
soles and stronger analgesia (including oral morphine) were
suggested, these failed to control the symptoms. Although
this was followed by physiotherapy and multiple guanethi-
dine blocks, symptoms remained uncontrolled and caused
signiﬁcant disability 18 months after the patient’s ﬁrst GP
visit.
In the following weeks the patient developed progressive
weight loss, fatigue, and muscle wasting below the knee. He
noticed for the ﬁrst time a ﬁrm round mass (approximately
15cm) on the lower aspect of the posterior thigh. He was re-
ferred back to Orthopaedics and an urgent MRI conﬁrmed2 Case Reports in Medicine
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Figure1:UrgentMRIoftherightlowerlimb;T1weighted(left),T2
weighted (right). A large (approx. 15cm), oval, smoothly deﬁned
heterogenous mass with a large necrotic centre is clearly visible be-
hind the lower femur (white arrows). There is also an area of al-
tered signal within the femur itself involving the condyle, suggest-
ive of bony metastasis (white arrowheads). The likely diagnosis is
malignantperipheralnervesheathtumor(MPNST)withadiﬀeren-
tialdiagnosisoflymphomaorothersofttissuesarcoma.Thecharac-
ter and distribution of the pain could signify a sciatic nerve origin.
an oval, smoothly deﬁned heterogenous mass in addition
to signal changes in both right and left femurs, most likely
representing metastatic foci (Figure 1).
The appearances were most suggestive of metastatic
malignant peripheral nerve sheath tumour (MPNST), and
the patient was urgently referred to Oncology. Chest CT and
whole-body MRI revealed the presence of multiple lung and
bonemetastases,consistentwithstageIVbmalignantdisease.
Predisposing factors for this rare malignancy including NF-
1 were considered. A detailed clinical examination revealed
freckling of the right axillary region. In addition, the histol-
ogy slides from the patient’s abdominal skin nodule biopsy
werereexaminedbyaspecialist.Theinitialﬁbromadiagnosis
was inconsistent with histopathological ﬁndings, which were
more in keeping with an intraneural neuroﬁbroma, part of a
plexiform neuroﬁbroma.
BasedontheNationalInstituteofHealth(NIH)diagnos-
ticcriteria,thepatientwasdiagnosedwithneuroﬁbromatosis
typeI[1].Thepatientwasstartedonpalliativechemotherapy
with doxorubicin, but unfortunately died 4 months later,
almost 24 months from his initial complaint.
2. Discussion
Type I neuroﬁbromatosis (NF-1) is a common autosomal
dominant neurocutaneous disorder, characterized by multi-
ple caf´ e au lait spots, axillary and inguinal freckling, multiple
cutaneousneuroﬁbromas,andirisLischnodules[2].Clinical
diagnosis of NF-1 is made using the 1988 NIH diagnostic
criteria presented in Table 1.
Table 1: National Institute of Health diagnostic criteria for
neuroﬁbromatosis type I [1]. The criteria are met in an individual
if two or more of the features listed are present.
Diagnosis of neuroﬁbromatosis type 1 (NF1)
(1) Six or more caf´ e au lait macules >5mm in greatest diameter in
prepubertal individuals and >15mm in greatest diameter in
postpubertal individuals
(2) Two or more neuroﬁbromas of any type or one plexiform
neuroﬁbroma
(3) Freckling in the axillary or inguinal regions (Crowe’s sign)
(4) Optic glioma
(5) Two or more Lisch nodules (iris hamartomas)
(6) A distinctive osseous lesion such as sphenoid dysplasia or
thinning of long bone cortex with or without pseudoarthrosis
(7) A ﬁrst-degree relative (parent, sibling, or oﬀspring) with NF1
by the above criteria
NF-1 is caused by loss of function mutations in the
NF1 gene in 17q11.2. This leads to defective production of
neuroﬁbromin, a guanosine triphosphatase-activating
protein that helps maintain the protooncogene Ras in its
inactive form [3]. Loss of neuroﬁbromin predisposes to in-
creased tumorigenesis, and malignant disease can appear in
either childhood or adulthood, with malignant peripheral
nerve sheath tumours (MPNSTs) being most common [4].
Several pathways are thought to be involved in the develop-
ment of tumours associated with NF1: rat sarcoma viral
oncogene homologue (RAS)-mitogen-activated protein kin-
ase (MAPK), mammalian target of rapamycin (mTOR), and
P21 protein (Cdc42/Rac)-activated kinase 1 (PAK1) [5, 6].
NF-1 patients have a lifetime risk of 8–13% to develop
MPNSTs, which are the leading cause of NF1-related mor-
tality. In current clinical practice the diagnosis of MPNST
should always be considered in NF-1 patients, especially
thosewithpersistentpain(thatlastsover1monthordisturbs
sleep), new neurological deﬁcits, or alteration in the char-
acteristics of a known neuroﬁbroma [7]. Surgical resection
is the mainstay of treatment; however, because of increased
metastatic potential and resistance to chemotherapy and
radiation the prognosis is poor. Five-year survival rates still
only reach 20–50%, despite latest eﬀorts to identify potential
molecular targets [8].
MPNSTs should be included in the diﬀerential diagnosis
of persistent or atypical pain in a young adult. Although
rare, these malignancies are commonly associated with NF-1
and can be the ﬁrst manifestation of the disease, as this case
illustrates. Early diagnosis is paramount as survival rates are
extremely poor in advanced stages of the malignancy.
3. Conclusion
MPNSTs can present with atypical symptoms in the young
adult population and are often diﬃcult to diagnose in previ-
ously healthy individuals. Unexplained pain that causes sig-
niﬁcant disability despite strong analgesia should be thor-
oughly investigated until serious underlying malignancy is
excluded. Although not exclusively associated with NF-1,Case Reports in Medicine 3
detection of an MPNST should prompt the physician to con-
sider the diagnosis and seek specialist help.
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